The effect of methotrexate on mouse bone cells in culture
Authors:
- Don MercillDMDon Mercill
Open Access
- 1 March 1996
- journal article
- basic science
- Published by Wiley in Arthritis & Rheumatism
- Vol. 39 (3) , 489-494
Abstract
Objective. We have recently shown that administration of long‐term, low‐dose methotrexate (MTX) causes severe osteopenia in female rats. This osteopenia is characterized both by decreased osteoblast function without a decrease in osteoblast numbers, and by increased bone resorption that is believed to represent a physiologic remodeling response by osteoclasts. The present study investigates the effects of varying doses of MTX on mouse bone cells in culture.Methods. Cells were obtained by sequential digestion of neonatal mouse calvariae, and cultured with fetal calf serum (10% for osteoblast‐like cells and 2% for osteoclast‐like cells). After 1 week, MTX was added to each culture in concentrations of 0.6 μM, 0.4 μM, 0.2 μM, 0.1 μM, 1 nM, and 0.5 nM. All experiments were done on 24 wells for each MTX concentration and for the controls. The effect on osteoblastic cells was assessed, at 7 days, by cell counts and by measurement of lysate alkaline phosphatase and supernatant osteocalcin levels, and, at 21 days, by analysis of the calcified matrix production, which was cultured with ascorbic acid and β‐glycerophosphate. For osteoclastic cells, cell count and lysate acid phosphatase levels were determined.Results. Levels of osteoblastic cells and lysate alkaline phosphatase were not changed by any of the concentrations of MTX. Matrix calcification and supernatant osteocalcin levels were diminished by MTX in a dose‐responsive manner. Osteoclast‐like cell numbers and acid phosphatase levels were not significantly affected by MTX.Conclusion. These results suggest that diminished mouse osteoblastic cell function occurs with very low mean concentrations of MTX, in a dose‐responsive manner. The mechanism seems to be inability of the cell to synthesize and calcify matrix, possibly through defective osteocalcin production. Thus, low‐dose MTX may have an important impact on bone density by slowing osteoblastic matrix production.Keywords
This publication has 16 references indexed in Scilit:
- Effects of methotrexate on human osteoblasts in vitro: Modulation by 1,25-dihydroxyvitamin D3Journal of Bone and Mineral Research, 1995
- Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patientsArthritis & Rheumatism, 1994
- The Effect of Low‐Dose Methotrexate on Bone Metabolism and Histomorphometry in RatsArthritis & Rheumatism, 1994
- Methotrexate osteopathy in rheumatic disease.Annals of the Rheumatic Diseases, 1993
- Morphologic characterization of osteoblast-like cell cultures isolated from newborn rat calvariaCalcified Tissue International, 1990
- Methotrexate osteopathySkeletal Radiology, 1984
- Differential serum dependence of cultured osteoclastic and osteoblastic bone cellsCalcified Tissue International, 1983
- Biochemical Characterization with Parathormone and Calcitonin of Isolated Bone Cells: Provisional Identification of Osteoclasts and OsteoblastsEndocrinology, 1976
- Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cellsNature, 1974
- Radiological Evidence of Growth in Children with Acute Leukemia Treated with Folic Acid AntagonistsRadiology, 1954